Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:NTES News 20 November 2025 - 16 January 2026

Hang Seng slips as tech drags again, while chip and AI names buck the trend in Hong Kong

Hang Seng slips as tech drags again, while chip and AI names buck the trend in Hong Kong

The Hang Seng Index closed down 0.29% in Hong Kong on Friday, pressured by losses in shipping, casino, and healthcare stocks. Ctrip shares plunged 19% the previous day after news of a China antitrust probe, rattling investors. Semiconductor stocks rose, with Hua Hong Semiconductor up 7.39%. Mainland investors sold about HK$600 million in Hong Kong shares via Stock Connect.
16 January 2026
············
NetEase (NTES) Q3 2025 Earnings Today: Revenue Miss, $5B Buyback Extension and Blizzard Pipeline Move the Stock

NetEase (NTES) Q3 2025 Earnings Today: Revenue Miss, $5B Buyback Extension and Blizzard Pipeline Move the Stock

NetEase Inc. (NASDAQ: NTES) reported Q3 2025 net revenue of RMB 28.4 billion (+8.2% YoY) but missed Wall Street estimates, even as gaming growth, a $5 billion share repurchase extension, a fresh dividend and Blizzard titles like Diablo IV shape the company’s outlook. Snapshot: What Happened With NetEase Today Chinese internet and gaming giant NetEase, Inc. (NASDAQ: NTES; HKEX: 9999) reported its Q3 2025 unaudited financial results before the market opened on November 20, 2025. Revenue grew, profit rose, and cash piled up, but top-line and bottom-line numbers came in below analyst expectations, prompting an early sell-off before shares later
20 November 2025
···

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop